|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 770,000 KRW | -1.28% |
|
-1.41% | +1.32% |
| Apr. 25 | Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe | MT |
| Apr. 25 | Samsung Biologics Posts Higher Q1 Profit, Sales | MT |
This is an abstract of the document. To keep reading, click here and get access to the original version.
Attachments
Disclaimer
Samsung Biologics Co. Ltd. published this content on 14 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 March 2024 01:58:02 UTC.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.32% | 39.82B | |
| -4.66% | 86.13B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B | |
| +2.29% | 7.72B |
SAMSUNG BIOLOGICS CO.,LTD. 
